These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 1203853)

  • 1. Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.
    Jones SE; Durie BG; Salmon SE
    Cancer; 1975 Jul; 36(1):90-7. PubMed ID: 1203853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model.
    Fan C; Georgiou KR; Morris HA; McKinnon RA; Keefe DMK; Howe PR; Xian CJ
    Breast Cancer Res Treat; 2017 Aug; 165(1):41-51. PubMed ID: 28550626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LINC00460-FUS-MYC feedback loop drives breast cancer metastasis and doxorubicin resistance.
    Yang L; Wang M; Wang Y; Zhu Y; Wang J; Wu M; Guo Q; Han X; Pandey V; Wu Z; Lobie PE; Zhu T
    Oncogene; 2024 Apr; 43(17):1249-1262. PubMed ID: 38418543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracyclines React with Apurinic/Apyrimidinic Sites in DNA.
    Bellamri M; Terrell JT; Brandt K; Gruppi F; Turesky RJ; Rizzo CJ
    ACS Chem Biol; 2023 Jun; 18(6):1315-1323. PubMed ID: 37200590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A careful reassessment of anthracycline use in curable breast cancer.
    Hurvitz SA; McAndrew NP; Bardia A; Press MF; Pegram M; Crown JP; Fasching PA; Ejlertsen B; Yang EH; Glaspy JA; Slamon DJ
    NPJ Breast Cancer; 2021 Oct; 7(1):134. PubMed ID: 34625570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug combination and repurposing for cancer therapy: the example of breast cancer.
    Correia AS; Gärtner F; Vale N
    Heliyon; 2021 Jan; 7(1):e05948. PubMed ID: 33490692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis.
    Li X; Sigworth EA; Wu AH; Behrens J; Etemad SA; Nagpal S; Go RS; Wuichet K; Chen EJ; Rubinstein SM; Venepalli NK; Tillman BF; Cowan AJ; Schoen MW; Malty A; Greer JP; Fernandes HD; Seifter A; Chen Q; Chowdhery RA; Mohan SR; Dewdney SB; Osterman T; Ambinder EP; Buchbinder EI; Schwartz C; Abraham I; Rioth MJ; Singh N; Sharma S; Gibson MK; Yang PC; Warner JL
    Sci Rep; 2020 Oct; 10(1):17536. PubMed ID: 33067482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.
    Younis T; Rayson D; Skedgel C
    Curr Oncol; 2011 Dec; 18(6):e288-96. PubMed ID: 22184496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer.
    Tomao S; Romiti A; Tomao F; Di Seri M; Caprio G; Spinelli GP; Terzoli E; Frati L
    BMC Cancer; 2006 May; 6():137. PubMed ID: 16723016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic arterial infusion chemotherapy for liver metastases from breast cancer.
    Arai Y; Sone Y; Inaba Y; Ariyoshi Y; Kido C
    Cancer Chemother Pharmacol; 1994; 33 Suppl():S142-4. PubMed ID: 8137476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of chemotherapy using ifosfamide with doxorubicin in advanced breast cancer.
    Millward M; Lind M; Gumbrell L; Robinson A; Lennard T; Cantwell B
    Breast Cancer Res Treat; 1994; 29(3):271-7. PubMed ID: 8049461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.
    Schell FC; Yap HY; Hortobagyi GN; Issell B; Esparza L
    Cancer Chemother Pharmacol; 1982; 7(2-3):223-5. PubMed ID: 7083463
    [No Abstract]   [Full Text] [Related]  

  • 13. Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen.
    Perez Manga G; Madrigal Alonso P; Alburquerque Carbuccia H
    Cancer Chemother Pharmacol; 1982; 7(2-3):231-3. PubMed ID: 6896298
    [No Abstract]   [Full Text] [Related]  

  • 14. [The antiestrogen tamoxifen in advanced breast cancer (author's transl)].
    Margreiter R
    Langenbecks Arch Chir; 1980; 351(4):249-62. PubMed ID: 6779066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive chemotherapy for solid tumours--current clinical applications.
    Kaye SB
    Cancer Chemother Pharmacol; 1982; 9(3):127-33. PubMed ID: 6761009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor status and adjuvant polychemotherapy or antiestrogen therapy in patients with high-risk breast cancer.
    Jonat W; Maass H; Braun M; Winter G
    J Cancer Res Clin Oncol; 1984; 107(3):233-7. PubMed ID: 6736112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer.
    Smalley RV; Lefante J; Bartolucci A; Carpenter J; Vogel C; Krauss S
    Breast Cancer Res Treat; 1983; 3(2):209-20. PubMed ID: 6688538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy of breast cancer.
    Perlow LS; Holland JF
    Med Oncol Tumor Pharmacother; 1984; 1(3):169-92. PubMed ID: 6400037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An assessment of current achievements in the systemic management of breast cancer.
    Lippman ME
    Breast Cancer Res Treat; 1984; 4(2):69-77. PubMed ID: 6378282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-dependent response to chemotherapy for carcinoma of the breast.
    Whitehouse JM
    J R Soc Med; 1985; 78 Suppl 9(Suppl 9):18-22. PubMed ID: 4045914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.